Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 2/20 | 0.34 |
| ▸ | HTRA2 | O43464 | 7/20 | 0.32 |
| ▸ | HTRA1 | Q92743 | 7/20 | 0.32 |
| ▸ | ALB | P02768 | 1/20 | 0.32 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14217406 | 0.97 | SLC5A2 (0.34) | SLC5A2HTRA2HTRA1ALBHAVCR2 | |
| SCHEMBL13338350 | 0.89 | SLC5A2 (0.32) | SLC5A2HTRA2HTRA1 | |
| SCHEMBL14217405 | 0.89 | SLC5A2 (0.32) | SLC5A2HTRA2HTRA1 | |
| SCHEMBL12373128 | 0.86 | SLC5A2 (0.31) | SLC5A2 | |
| SCHEMBL14240023 | 0.85 | SLC5A2 (0.32) | SLC5A2CA12CA1CA2CA9 | |
| SCHEMBL13366935 | 0.82 | KMT2A (0.34) | SLC5A2HAVCR2CA12CA1CA2 | |
| SCHEMBL12373110 | 0.81 | — | — | |
| SCHEMBL12373127 | 0.80 | SLC5A2 (0.30) | SLC5A2 | |
| SCHEMBL12373111 | 0.77 | — | — | |
| SCHEMBL14239765 | 0.77 | TERT (0.32) | SLC5A2CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835625-B2 | Propargyl substituted nucleoside compounds and methods | APPLIED BIOSYSTEMS, LLC (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120309953-A1 | Propargyl Substituted Nucleoside Compounds and Methods | Life Technologies Corporation (US) | 2012-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309953-A1 | Propargyl Substituted Nucleoside Compounds and Methods | PNP, NUDT1, DUT | SLC5A2 2705/4885HTRA2 3110/4885HTRA1 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.